A phase 2 trial of ponsegromab has shown promising results in treating cancer cachexia, a condition that leads to severe weight and muscle loss, according to a study published Sept. 14 in the New England Journal of Medicine.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
